Prescription drug · ANDA
Droxidopa NDC 59651-375
Droxidopa 100 mg/1 · Capsule · Oral · Aurobindo Pharma Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 59651-375-90 | 5965103759059651037590 | 90 CAPSULE in 1 BOTTLE (59651-375-90)Marketed from Feb 18, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Droxidopa
- Generic name (nonproprietary)
- droxidopa
- Active ingredients
- Droxidopa — 100 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Aurobindo Pharma LimitedNDC labeler code 59651
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 214387
- Marketing start
- Listing expires
- Other FDA classes
- Catecholamines (Chemical structure)Increased Blood Pressure (Physiologic effect)
- Identifiers
- Product ID 59651-375_eb94f573-c790-4392-95a4-ff99a81a181fSPL ID eb94f573-c790-4392-95a4-ff99a81a181fSPL set ID ff263c9a-3db2-45ac-9ba6-8fca47199604RxCUI 1490026, 1490034, 1490038UNII J7A92W69L7
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N459651037590followed by a unit qualifier and the quantityPackage 59651-0375-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of droxidopa capsules should be assessed periodically. Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to blac…
Excerpt only. Read the full label for complete information.
About NDC 59651-375
- What is NDC 59651-375?
- 59651-375 is the product NDC for Droxidopa, Droxidopa 100 mg/1 capsule, listed with the FDA by Aurobindo Pharma Limited. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Droxidopa.
- What is the active ingredient?
- Droxidopa.
- Who is the labeler?
- Aurobindo Pharma Limited, NDC labeler code 59651. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Droxidopa?
- 41 other product NDCs are listed under this name. See all Droxidopa NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Droxidopa products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Droxidopa | Droxidopa 100 mg/1 | CapsuleOral | CivicaScript LLC | 82249-551 | 82249-0551-90 |
| Droxidopa | Droxidopa 200 mg/1 | CapsuleOral | CivicaScript LLC | 82249-552 | 82249-0552-90 |
| Droxidopa | Droxidopa 300 mg/1 | CapsuleOral | CivicaScript LLC | 82249-554 | 82249-0554-90 |
| droxidopa | Droxidopa 100 mg/1 | CapsuleOral | Slate Run Pharmaceuticals, LLC | 70436-140 | 70436-0140-06 |
| droxidopa | Droxidopa 200 mg/1 | CapsuleOral | Slate Run Pharmaceuticals, LLC | 70436-141 | 70436-0141-06 |
| droxidopa | Droxidopa 300 mg/1 | CapsuleOral | Slate Run Pharmaceuticals, LLC | 70436-142 | 70436-0142-06 |
| Droxidopa | Droxidopa 100 mg/1 | CapsuleOral | Bionpharma Inc. | 69452-256 | 69452-0256-19 |
| Droxidopa | Droxidopa 200 mg/1 | CapsuleOral | Bionpharma Inc. | 69452-257 | 69452-0257-19 |
| Droxidopa | Droxidopa 300 mg/1 | CapsuleOral | Bionpharma Inc. | 69452-258 | 69452-0258-19 |
| Droxidopa | Droxidopa 100 mg/1 | CapsuleOral | Lupin Pharmaceuticals, Inc. | 68180-987 | — |
Other NDCs under ANDA 214387
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Droxidopa | Droxidopa 200 mg/1 | CapsuleOral | Aurobindo Pharma Limited | 59651-376 |
| Droxidopa | Droxidopa 300 mg/1 | CapsuleOral | Aurobindo Pharma Limited | 59651-377 |